Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | HSPA5 | P11021 | 3/20 | 0.37 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.37 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3534007 | 0.74 | CASP3 (0.36) | HTTCASP3HSPA5HSPA9HSPA2 | |
| SCHEMBL3534370 | 0.69 | HTT (0.57) | HTTALDH1A1 | |
| SCHEMBL3530038 | 0.68 | HTT (0.46) | HTTALDH1A1 | |
| SCHEMBL7899427 | 0.66 | CASP3 (0.61) | CASP3PIN1 | |
| SCHEMBL10173305 | 0.66 | CASP3 (0.58) | CASP3PIN1 | |
| SCHEMBL13044090 | 0.66 | CASP3 (0.58) | CASP3PIN1 | |
| SCHEMBL21254233 | 0.65 | CASP3 (0.57) | CASP3PIN1 | |
| SCHEMBL9269948 | 0.65 | CASP3 (0.57) | CASP3PIN1 | |
| SCHEMBL18078728 | 0.65 | CASP3 (0.53) | CASP3PIN1 | |
| SCHEMBL3868193 | 0.65 | MDM4 (0.50) | CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742925-B1 | SUBSTITUTED 5, 6, 7, 8-TETRAHYDRO-PYRIDO[4, 3-D]PYRIMIDINE-2-YL COMPOUNDS AND 5, 6, 7, 8-TETRAHYDRO-QUINAZOLINE-2-YL COMPOUNDS | GRUENENTHAL GMBH (DE) | 2014-04-23 | — | — | EP | claimed |
| US-20070249631-A1 | Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds | GRUENENTHAL GMBH (DE) | 2007-10-25 | — | — | US | claimed |
| US-7662828-B2 | Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds | GRUENENTHAL GMBH (DE) | 2010-02-16 | — | — | US | disclosed |
| US-20090176811-A1 | Substituted 5,6,7,8-Tetrahydro-pyrido[4,3-d]pyrimidine-2-yl Compounds and 5,6,7,8-Tetrahydro-quinazoline-2-yl Compounds | GRUENENTHAL GMBH (DE) | 2009-07-09 | — | — | US | disclosed |
| US-20070249631-A1 | Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds | GRUENENTHAL GMBH (DE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249631-A1 | Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds | P2RX7, CYP2C8, P2RX5 | HTT 858/4885CASP3 1879/4885HSPA5 3853/4885 |
| US-20090176811-A1 | Substituted 5,6,7,8-Tetrahydro-pyrido[4,3-d]pyrimidine-2-yl Compounds and 5,6,7,8-Tetrahydro-quinazoline-2-yl Compounds | P2RX7, P2RX5, DPYD | HTT 1459/4885CASP3 1912/4885HSPA5 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.